RecruitingNCT05129605
Prostate Cancer Genetic Risk Evaluation and Screening Study
Studying Ataxia-telangiectasia variant
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Keyan Salari, MD, PhDMassachusetts General Hospital
- Intervention
- Prostate cancer screening(diagnostic_test)
- Enrollment
- 400 enrolled
- Eligibility
- 35-74 years · MALE
- Timeline
- 2020 – 2040
Study locations (1)
- Massachusetts General Hospital, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05129605 on ClinicalTrials.govOther trials for Ataxia-telangiectasia variant
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07224308Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mmThe Levine Center for Plastic Surgery
- ACTIVE NOT RECRUITINGPHASE2NCT06033092Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTionEuropean Institute of Oncology
- ACTIVE NOT RECRUITINGPHASE2NCT04030559Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response DefectsMarc Dall'Era, MD